STI care · testing · partner follow-up
Azithromycin for STI Treatment Depends on Testing
Azithromycin has a limited, condition-specific role in current STI care. CDC recommends doxycycline for most adolescent and adult chlamydia infections, with azithromycin as an alternative in defined circumstances and a recommended option during pregnancy. Azithromycin is no longer routine gonorrhea therapy. Testing by exposure site, pregnancy, adherence, partners, and follow-up shape the plan.
Medically reviewed by
Infectious diseases and antimicrobial stewardship
Medical review completed August 27, 2026
Build STI treatment around the diagnosed infection
A symptom-based antibiotic request can miss asymptomatic infection, coinfection, a different exposure site, or a complication. Current care connects history and testing to treatment, partner management, prevention, and retesting.
Test the sites of exposure
Urine or genital testing alone may not address rectal or pharyngeal exposure; the clinician selects appropriate specimens.
Use the current regimen
Treatment differs for chlamydia, gonorrhea, pregnancy, allergies, infection site, and adherence concerns.
Prevent reinfection
Follow instructions about partners, sexual activity, additional STI testing, and the recommended retesting interval.
Azithromycin’s STI role is not interchangeable
Guidance has changed as evidence and resistance patterns evolved. The table shows why the organism and context must be established before treatment. For more detail on this decision, review Azithromycin uses and diagnosis.
| Situation | Azithromycin role | Additional need |
|---|---|---|
| Adult chlamydia | Alternative in defined cases | Site and adherence review |
| Pregnant chlamydia | Recommended regimen option | Test of cure and retesting |
| Rectal chlamydia | Lower efficacy concern | Guideline-preferred therapy |
| Gonorrhea | Not routine treatment | Ceftriaxone-based guidance |
| Partner exposure | Not automatic sharing | Evaluation or lawful EPT |
Do not use an older gonorrhea regimen from memory. CDC removed routine azithromycin dual therapy because of resistance and stewardship concerns. Testing, current ceftriaxone-based guidance, and separate chlamydia management now direct care.
Exposure-site testing changes the treatment question
Chlamydia and gonorrhea can occur at genital, rectal, and pharyngeal sites, and symptoms may be absent. A confidential history identifies sites that need testing. Nucleic acid amplification tests are widely used, while culture and susceptibility testing become important when gonorrhea treatment failure is suspected.
A single antibiotic chosen before testing can miss coinfection, expose an uninfected person unnecessarily, or inadequately treat an infection at a site where effectiveness differs. Additional HIV, syphilis, and gonorrhea or chlamydia testing may be recommended based on the diagnosis and risk context.
Chlamydia guidance gives azithromycin a defined role
CDC recommends doxycycline for most adolescents and adults with chlamydia. Azithromycin is an alternative when adherence to a multiday regimen is a substantial concern, but post-treatment evaluation or testing may be needed because effectiveness is lower for rectal infection. During pregnancy, CDC lists azithromycin as the recommended regimen and calls for a test of cure.
These are clinician-directed regimens with specific dosing in the guideline, not instructions to self-treat. Pregnancy, infection site, allergy, ability to follow the regimen, symptoms of pelvic inflammatory disease, and access to follow-up all influence care. A related clinical question is covered in Respiratory infection decisions.
Gonorrhea treatment changed because resistance matters
Azithromycin was previously paired with a cephalosporin in U.S. gonorrhea guidance. CDC now recommends ceftriaxone alone for gonorrhea, with antichlamydial treatment when chlamydia has not been excluded. The change reflects increasing azithromycin resistance, stewardship, and concern about effects on other pathogens and the microbiome.
Suspected treatment failure requires culture and antimicrobial susceptibility testing because a routine NAAT does not show susceptibility. Persistent symptoms, re-exposure, or a positive follow-up result needs clinician review rather than another unverified antibiotic course.
Partner care and retesting complete treatment
Treating one person without addressing partners can lead to reinfection and continued transmission. CDC guidance describes partner evaluation and treatment, with expedited partner therapy only where permitted and appropriate. Patients should receive clear written information about allergies, adverse effects, and complication warning signs.
Follow instructions on avoiding sexual activity until treatment requirements are met for the patient and partners. Retesting is commonly recommended because repeat infection is frequent. Severe pelvic or abdominal pain, testicular pain, fever, pregnancy with concerning symptoms, or worsening illness deserves prompt assessment.
- Partner notification
- Site-specific testing
- Additional STI screening
- Abstinence instructions
- Retesting plan
- Urgent symptom review
STI treatment questions
Is azithromycin first-line treatment for chlamydia?
Doxycycline is the CDC-recommended regimen for most adolescents and adults. Azithromycin remains an alternative in defined circumstances and is recommended during pregnancy, with context-specific follow-up.
Can azithromycin treat gonorrhea?
It is no longer routine gonorrhea treatment in U.S. CDC guidance. Ceftriaxone-based treatment is recommended, with separate antichlamydial therapy when chlamydia has not been excluded.
Why does rectal exposure matter?
Treatment effectiveness differs by infection site. Rectal chlamydia has lower treatment efficacy with azithromycin than doxycycline, so exposure-site testing and guideline-directed selection are important.
Should my partner take my azithromycin?
No. Partner care should follow clinician and public-health guidance, including lawful expedited partner therapy where applicable. Sharing a personal prescription bypasses allergy, interaction, pregnancy, and diagnosis checks.
When is retesting needed?
CDC recommends retesting after chlamydia or gonorrhea treatment because reinfection is common. Pregnancy and suspected treatment failure have additional test-of-cure or culture considerations.
Primary sources
Clinical statements on this page are bounded by the current prescribing information and U.S. public-health guidance below.
- Centers for Disease Control and Prevention: Chlamydial Infections — STI Treatment Guidelines (reviewed 2021-07-22)
- Centers for Disease Control and Prevention: Gonococcal Infections Among Adolescents and Adults (accessed 2026-08-27)
- U.S. National Library of Medicine: Azithromycin tablet, film coated — prescribing information (label updated 2026-06-16)
This educational page does not replace diagnosis, prescribing advice, or urgent medical care. A clinician must decide whether an antibiotic is appropriate for an individual infection and medical history.